Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma 3Urogenital Neoplasms 2Prostatic Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Male Urogenital Diseases 2Genital Neoplasms, Male 2Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases, Male 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

padeliporfin 2talazoparib 1sipuleucel-T 1luprolide acetate gel depot 1ixabepilone 1enzalutamide 1Therapeutics 1Pluvicto 1Paclitaxel 1Nivolumab 1Leuprolide 1Ipilimumab 1Imatinib Mesylate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Diseases × padeliporfin × Clear all
NCT00707356 2016-04-19

Study of WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

Phase 2 Completed
42 enrolled
Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00975429 2015-04-28

Study Using WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

Phase 2 Completed
86 enrolled
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡